Medindia

X

Pfizer Loses Viagra Patent in Canada

by Kathy Jones on  November 9, 2012 at 8:50 PM Drug News   - G J E 4
Canada's Supreme Court has canceled Pfizer's patent for Viagra as the company was not able to specify the active compound of the drug in its patent.

"Patent 2,163,446 is void," the Supreme Court said in its ruling.
 Pfizer Loses Viagra Patent in Canada
Pfizer Loses Viagra Patent in Canada
Advertisement

The court explained that under Canadian patent rules an inventor must "properly disclose the invention and how it works" in order to be granted "exclusive monopoly rights" for it.

It concluded that Pfizer knew and did not properly disclose that sildenafil is the only compound in Viagra, out of several listed compounds, that induces penile erection in impotent males.

"The patent system is based on a 'bargain,' or quid pro quo: the inventor is granted exclusive rights in a new and useful invention for a limited period in exchange for disclosure of the invention so that society can benefit from this knowledge," the court said.

"If there is no proper disclosure, then there can be no exclusive monopoly rights."

Generic pharmaceutical company Teva brought the suit against Pfizer hoping to produce a generic version of Viagra before Pfizer's patent was due to expire in 2014.

The high court noted Pfizer had conducted tests proving sildenafil was the key to treating erectile dysfunction, and so concluded that "the invention was the use of sildenafil for the treatment of ED."

But Pfizer's patent only states that "one of the compounds (in Viagra) induces penile erection in impotent males, without specifying which is the effective compound."

Source: AFP

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
Advertisement